$Correction: Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.$

Correction: Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.

[This corrects the article DOI: 10.1371/journal.pone.0217881.].

Bibliographic Details
Main Authors:	Paola Anna Jablonska, Ricardo Diez-Valle, Jaime Gállego Pérez-Larraya, Marta Moreno-Jiménez, Miguel Ángel Idoate, Leire Arbea, Sonia Tejada, Maria Reyes Garcia de Eulate, Luis Ramos, Javier Arbizu, Pablo Domínguez, José Javier Aristu
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0219614

Similar Items

Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
by: Paola Anna Jablonska, et al.
Published: (2019-01-01)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
by: Makoto Ohno, et al.
Published: (2019-11-01)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
by: Georges Noël, et al.
Published: (2013-09-01)

Hypofractionated Radiation Therapy with Temozolomide for Patients with Glioblastoma Multiforme Recursive Partitioning Analyzes Class V and VI
by: Fuzuli Tuğrul, et al.
Published: (2019-09-01)

Panobinostat Potentiates Temozolomide Effects and Reverses Epithelial–Mesenchymal Transition in Glioblastoma Cells
by: Alejandro Urdiciain, et al.
Published: (2018-02-01)

In vitro therapy against glioblastoma cells by 3-Dezaneplanocin-A, panobinostat, and temozolomide
by: Javier de la Rosa, et al.
Published: (2018-01-01)

HYPOFRACTIONATED RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME
by: Sadaf Usman, et al.
Published: (2015-11-01)

A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
by: Susana Inogés, et al.
Published: (2017-05-01)

Concurrent Hypofractionated Three-dimensional Re-irradiation and Temozolomide in Recurrent Malignant Glioma
by: Doaa Ali Sharaf Eldeen, et al.
Published: (2012-04-01)

Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.
by: Christine Carico, et al.
Published: (2012-01-01)

Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
by: Liangzhi Zhong, et al.
Published: (2019-06-01)

Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
by: Pingde Zhang, et al.
Published: (2018-01-01)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
by: Dipongkor Saha, et al.
Published: (2020-06-01)

Strategies of temozolomide in future glioblastoma treatment
by: Lee CY
Published: (2017-01-01)

Mechanism of acquired temozolomide resistance in glioblastoma
by: McFaline-Figueroa, José L
Published: (2014)

Tbx2 confers poor prognosis in glioblastoma and promotes temozolomide resistance with change of mitochondrial dynamics
by: Yi F, et al.
Published: (2017-02-01)

Considering the Experimental use of Temozolomide in Glioblastoma Research
by: Verena J. Herbener, et al.
Published: (2020-06-01)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
by: Hannah Strobel, et al.
Published: (2019-09-01)

Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
by: Hyungsin Kim, et al.
Published: (2019-09-01)

Short Course Hypofractionated Radiotherapy versus Conventional Radiotherapy for Poor Prognosis Glioblastoma Multiforme: A Randomised Controlled Trial
by: SUNIL CHOUDHARY, et al.
Published: (2019-03-01)

Reveal the involvement of CEBPD in stemness and Temozolomide resistance of glioblastoma
by: Wen-ChiLin, et al.
Published: (2018)

Nanoparticle Drug Delivery Systems for Temozolomide in the Treatment of Glioblastoma
by: Malini Honavar Melo Pires
Published: (2019)

Investigation of Temozolomide-resistant and sensitive clones in human glioblastoma
by: WU, YI-PING, et al.
Published: (2017)

Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
by: Yang He, et al.
Published: (2019-03-01)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
by: Thomas RP, et al.
Published: (2012-12-01)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
by: Monique eDontenwill, et al.
Published: (2012-10-01)

Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells
by: Beltzig, L., et al.
Published: (2022)

Aspergillosis in a Patient Receiving Temozolomide for the Treatment of Glioblastoma
by: Rodrigo Ramella Munhoz, et al.
Published: (2013-08-01)

Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications
by: Moreno Marta, et al.
Published: (2010-02-01)

Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model
by: Véronique Mathieu, et al.
Published: (2008-12-01)

Survival after hypofractionation in glioblastoma: a systematic review and meta-analysis
by: Jane-Chloe Trone, et al.
Published: (2020-06-01)

MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma
by: Vera Miranda-Gonçalves, et al.
Published: (2021-07-01)

Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide
by: Erkan Topkan, et al.
Published: (2020-01-01)

DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.
by: Amandine Etcheverry, et al.
Published: (2014-01-01)

The effects of physical microenvironment stimuli on Temozolomide-induced resistant glioblastoma
by: Cing-YanJhang, et al.
Published: (2019)

To investigate the effect of betulinic acid on temozolomide- resistant glioblastoma cells
by: Yung-Ning Huang, et al.
Published: (2018)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
by: Jingjing Ge, et al.
Published: (2021-02-01)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
by: Yu-Ling Tsai, et al.
Published: (2020-09-01)

Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma
by: Junseong Park, et al.
Published: (2019-01-01)

Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells
by: Bernd Kaina, et al.
Published: (2020-09-01)

Cannot write session to /tmp/vufind_sessions/sess_hfaj77irb7lk504gbjkpsq6nbg